A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anticancer activity against a broad spectrum of treatment-resistant cancers

Clinical Cancer Research

Volumn 22, Issue 18, 2016, Pages 4698-4711

  Karpel Massler, Georg ^a   Horst, Basil A ^a   Shu, Chang ^a   Chau, Lily ^a,c   Tsujiuchi, Takashi ^a   Bruce, Jeffrey N ^a   Canoll, Peter ^a   Greene, Lloyd A ^a   Angelastro, James M ^b   Siegelin, Markus D ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 5; ANTINEOPLASTIC AGENT; CASPASE; CELL PENETRATING PEPTIDE; DEUBIQUITINASE; MEMBRANE PROTEIN; NAVITOCLAX; PEPTIDE CP D N ATF5 S1; PROTEIN BAG3; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN USP9X; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ACTIVATING TRANSCRIPTION FACTOR; ANILINE DERIVATIVE; ATF5 PROTEIN, HUMAN; BIOLOGICAL MARKER; PEPTIDE; SULFONAMIDE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL SPECIFICITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; METABOLISM; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME;

ACTIVATING TRANSCRIPTION FACTORS; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; PEPTIDES; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973599317     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2827     Document Type: Article

References (50)

1. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
2. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Greene LA, Lee HY, Angelastro JM. The transcription factor ATF5: role in neurodevelopment and neural tumors. J Neurochem 2009;108:11-22.
5. Sheng Z, Evans SK, Green MR. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? Oncotarget 2010;1:457-60.
6. Li G, Li W, Angelastro JM, Greene LA, Liu DX. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. Mol Cancer Res 2009;7:933-43.
7. Vinson C, Acharya A, Taparowsky EJ.Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim Biophys Acta 2006;1759:4-12.
8. Al Sarraj J, Vinson C, Thiel G. Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP. Biol Chem 2005;386:873-9.
9. Watatani Y, Ichikawa K, Nakanishi N, Fujimoto M, Takeda H, Kimura N, et al. Stress-induced translation of ATF5 mRNA is regulated by the 50-untranslated region. J Biol Chem 2008;283:2543-53.
10. Zhou D, Palam LR, Jiang L, Narasimhan J, Staschke KA, Wek RC. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J Biol Chem 2008;283:7064-73.
11. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007;120:1883-90.
12. Ishihara S, Yasuda M, Ishizu A, Ishikawa M, Shirato H, Haga H. Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells. Oncotarget 2015;6:4602-14.
13. Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 2010;16:671-7.
14. Persengiev SP, Devireddy LR, Green MR. Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev 2002;16:1806-14.
15. Chen A, Qian D, Wang B, Hu M, Lu J, Qi Y, et al. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells. Int J Gynecol Pathol 2012;31:532-7.
16. Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 2006;25:907-16.
17. Arias A, Lame MW, Santarelli L, Hen R, Greene LA, Angelastro JM. Regulated ATF5 loss-of-function in adultmice blocks formation and causes regression/eradication of gliomas. Oncogene 2012;31:739-51.
18. Hu M, Wang B, Qian D, Li L, Zhang L, Song X, et al. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. Anticancer Res 2012;32:4385-94.
19. Cates CC, Arias AD, Nakayama Wong LS, Lame MW, Sidorov M, Cayanan G, et al. Regression/eradication of gliomas in mice by a systemicallydeliverable ATF5 dominant-negative peptide. Oncotarget. 2016. [Epub ahead of print].
20. Karpel-Massler G, Ba M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, et al. TIC10/ONC201 synergizeswith Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget 2015;6:36456-71.
21. Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, et al. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther 2013;12:1783-95.
22. Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest 2011;121: 1349-60.
23. Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res 2014;12: 987-1001.
24. Karpel-Massler G, Pareja F, Aime P, Shu C, Chau L, Westhoff MA, et al. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS ONE 2014;9:e114583.
25. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998;8:84-7.
26. Greene LA, Angelastro JM, inventors; The Trustees Of Columbia University In The City Of New York, assignee. Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5. United States patent US 2016/0046686 A1. 2016 Feb 18.
27. Angelastro JM, Ignatova TN, Kukekov VG, Steindler DA, Stengren GB, Mendelsohn C, et al. Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci 2003;23: 4590-600.
28. Moll JR, Olive M, Vinson C. Attractive interhelical electrostatic interactions in the proline-and acidic-rich region (PAR) leucine zipper subfamily preclude heterodimerization with other basic leucine zipper subfamilies. J Biol Chem 2000;275:34826-32.
29. Vinson CR, Hai T, Boyd SM. Dimerization specificity of the leucine zippercontaining bZIP motif on DNA binding: prediction and rational design. Genes Dev 1993;7:1047-58.
30. Dluzen D, Li G, Tacelosky D, Moreau M, Liu DX. BCL-2 is a downstream target of ATF5 thatmediates the prosurvival function of ATF5 in a cell typedependent manner. J Biol Chem 2011;286:7705-13.
31. Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem 2013;288:6980-90.
32. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-7.
33. Karpel-MasslerG, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, et al. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget 2015;6: 14507-21.
34. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88.
35. McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O'Hagan B, et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis 2010;1:e108.
36. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
37. Marini ES, Giampietri C, Petrungaro S, Conti S, Filippini A, Scorrano L, et al. The endogenous caspase-8 inhibitor c-FLIP regulates ER morphology and crosstalk with mitochondria. Cell Death Differ 2015;22:1131-43.
38. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27: 6398-406.
39. Li G, Xu Y, Guan D, Liu Z, Liu DX. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. J Biol Chem 2011;286:20251-9.
40. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005;121:1085-95.
41. Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res 2014;74:4731-40.
42. Festa M, Del Valle L, Khalili K, Franco R, Scognamiglio G, Graziano V, et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol 2011;178:2504-12.
43. Tse C, Shoemaker AR, Adickes J, AndersonMG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
44. Xie Y, Avello M, Schirle M, McWhinnie E, Feng Y, Bric-Furlong E, et al. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation. J Biol Chem 2013;288:2976-85.
45. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1876-84.
46. Cristofanon S, Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012;3:e432.
47. LucasKM,Mohana-Kumaran N,LauD,ZhangXD,Hersey P,HuangDC, et al. Modulation ofNOXAandMCL-1 as a strategy for sensitizingmelanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 2012;18:783-95.
48. Preuss E, Hugle M, Reimann R, SchlechtM, Fulda S. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J Biol Chem 2013;288:35287-96.
49. Vaillant F,MerinoD, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013;24:120-9.
50. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013;32: 1341-50.